Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy.
Antimicrobial drug development is increasingly lagging behind the evolution of antibiotic resistance, and as a result, there is a pressing need for new antibacterial therapies that can be readily designed and implemented. In this work, we engineered bacteriophage to overexpress proteins and attack gene networks that are not directly targeted by antibiotics. We show that suppressing the SOS network in Escherichia coli with engineered bacteriophage enhances killing by quinolones by several orders of magnitude in vitro and significantly increases survival of infected mice in vivo. In addition, we demonstrate that engineered bacteriophage can enhance the killing of antibiotic-resistant bacteria, persister cells, and biofilm cells, reduce the number of antibiotic-resistant bacteria that arise from an antibiotic-treated population, and act as a strong adjuvant for other bactericidal antibiotics (e.g., aminoglycosides and beta-lactams). Furthermore, we show that engineering bacteriophage to target non-SOS gene networks and to overexpress multiple factors also can produce effective antibiotic adjuvants. This work establishes a synthetic biology platform for the rapid translation and integration of identified targets into effective antibiotic adjuvants.
Lu
Timothy K
TK
Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA 02139, USA.
Collins
James J
JJ
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001435:Bacteriophages / Q000187:drug effects / Q000235:genetics*; D017024:Chemotherapy, Adjuvant; D024881:Drug Resistance, Bacterial / Q000187:drug effects; D004926:Escherichia coli / Q000166:cytology / Q000187:drug effects* / Q000235:genetics*; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D053263:Gene Regulatory Networks / Q000187:drug effects*; D005818:Genetic Engineering; D051379:Mice; D008826:Microbial Sensitivity Tests; D050296:Microbial Viability / Q000187:drug effects; D015363:Quinolones / Q000494:pharmacology; D013014:SOS Response, Genetics / Q000187:drug effects*; D016019:Survival Analysis
D000900:Anti-Bacterial Agents; D015363:Quinolones